Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deferred Tax Liability (2016 - 2021)

Assembly Biosciences (ASMB) has 7 years of Non-Current Deferred Tax Liability data on record, last reported at $2.5 million in Q3 2021.

  • For Q3 2021, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.5 million; the TTM value through Sep 2021 reached $2.5 million, changed 0.0%, while the annual FY2020 figure was $2.5 million, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability reached $2.5 million in Q3 2021 per ASMB's latest filing, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $3.3 million in Q4 2018 and bottomed at $2.1 million in Q4 2017.
  • Average Non-Current Deferred Tax Liability over 5 years is $2.7 million, with a median of $2.5 million recorded in 2019.
  • Peak YoY movement for Non-Current Deferred Tax Liability: crashed 80.79% in 2017, then surged 52.25% in 2018.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.1 million in 2017, then soared by 52.25% to $3.3 million in 2018, then decreased by 22.17% to $2.5 million in 2019, then changed by 0.0% to $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $2.5 million in Q3 2021, $2.5 million in Q2 2021, and $2.5 million in Q1 2021.